Name: rab10 phosphorylation detection by lrrk2 activity using sds-page with a phosphate-binding tag
Uploaded: 2017-12-14T14:00:00
Description: Mutations in leucine-rich repeat kinase 2 (LRRK2) have been shown to be linked with familial Parkinson&#39;s disease (FPD). Since abnormal activation of ...

We thank Dr. Takeshi Iwatsubo (University of Tokyo, Japan) for kindly providing the plasmids encoding 3xFLAG-LRRK2 WT and mutants. We also thank Dr. Dario Alessi (University of Dundee, UK) for kindly providing MLi-2 and the plasmid encoding HA-Rab10. This work was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number JP17K08265 (G.I.).

1. Sample Preparation for the P-tag SDS&#8211;PAGE
<ol>
	<li>Remove and discard the media from 10 cm dishes in which cells are grown using a suction and wash cells with 5 mL Dulbecco&#39;s phosphate-buffered saline (DPBS) by first adding DPBS to the side of the dishes to avoid disturbing the cell layer, and manually rock the dishes back and forth several times.</li>
	<li>Remove and discard the DPBS using a suction and add 2 mL of 0.25% (w/v) trypsin diluted in DPBS, and gently rock the dishes to cover the cell layer. P...

<ol>
	<li>Sveinbjornsdottir, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+clinical+symptoms+of+Parkinson's+disease.">The clinical symptoms of Parkinson's disease.</a> J. Neurochem. 139 (Suppl. 1), 318-324 (2016).</li><li>Hernandez, D. G., Reed, X., Singleton, A. B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Genetics+in+Parkinson+disease:+Mendelian+versus+non-Mendelian+inheritance.">Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance.</a> J. Neurochem. 139 (Suppl. 1), 59-74 (2016).</li><li>Pais&#225;n-Ru&#237;z, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Cloning+of+the+gene+containing+mutations+that+cause+PARK8-linked+Parkinson's+disease.">Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.</a> Neuron. 44 (4), 595-600 (2004).</li><li>Zimprich, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Mutations+in+LRRK2+cause+autosomal-dominant+parkinsonism+with+pleomorphic+pathology.">Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.</a> Neuron. 44 (4), 601-607 (2004).</li><li>Gilks, W. P., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+common+LRRK2+mutation+in+idiopathic+Parkinson's+disease.">A common LRRK2 mutation in idiopathic Parkinson's disease.</a> Lancet. 365 (9457), 415-416 (2005).</li><li>Satake, W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Genome-wide+association+study+identifies+common+variants+at+four+loci+as+genetic+risk+factors+for+Parkinson's+disease.">Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease.</a> Nat. Genet. 41 (12), 1303-1307 (2009).</li><li>Sim&#243;n-S&#225;nchez, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Genome-wide+association+study+reveals+genetic+risk+underlying+Parkinson's+disease.">Genome-wide association study reveals genetic risk underlying Parkinson's disease.</a> Nat. Genet. 41 (12), 1308-1312 (2009).</li><li>Klein, C., Ziegler, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Imputation+of+sequence+variants+for+identification+of+genetic+risks+for+Parkinson's+disease:+a+meta-analysis+of+genome-wide+association+studies.">Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies.</a> Lancet. 377 (9766), 641-649 (2011).</li><li>Cookson, M. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+role+of+leucine-rich+repeat+kinase+2+(LRRK2)+in+Parkinson's+disease.">The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease.</a> Nat. Rev. Neurosci. 11 (12), 791-797 (2010).</li><li>Ozelius, L. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=LRRK2+G2019S+as+a+Cause+of+Parkinson’s+Disease+in+Ashkenazi+Jews.">LRRK2 G2019S as a Cause of Parkinson’s Disease in Ashkenazi Jews.</a> N. Engl. J. Med. 354 (4), 424-425 (2006).</li><li>Lesage, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=LRRK2+G2019S+as+a+Cause+of+Parkinson’s+Disease+in+North+African+Arabs.">LRRK2 G2019S as a Cause of Parkinson’s Disease in North African Arabs.</a> N. Engl. J. Med. 354 (4), 422-423 (2006).</li><li>Bouhouche, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=LRRK2+G2019S+Mutation:+Prevalence+and+Clinical+Features+in+Moroccans+with+Parkinson's+Disease.">LRRK2 G2019S Mutation: Prevalence and Clinical Features in Moroccans with Parkinson's Disease.</a> Parkinsons. Dis. , 1-7 (2017).</li><li>West, A. B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Parkinson's+disease-associated+mutations+in+leucine-rich+repeat+kinase+2+augment+kinase+activity.">Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.</a> Proc. Natl. Acad. Sci. U. S. A. 102 (46), 16842-16847 (2005).</li><li>Ito, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=GTP+binding+is+essential+to+the+protein+kinase+activity+of+LRRK2,+a+causative+gene+product+for+familial+Parkinson's+disease.">GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease.</a> Biochemistry. 46 (5), 1380-1388 (2007).</li><li>Steger, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Phosphoproteomics+reveals+that+Parkinson's+disease+kinase+LRRK2+regulates+a+subset+of+Rab+GTPases.">Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases.</a> Elife. 5, (2016).</li><li>Ito, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Phos-tag+analysis+of+Rab10+phosphorylation+by+LRRK2:+a+powerful+assay+for+assessing+kinase+function+and+inhibitors.">Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors.</a> Biochem. J. 473, 2671-2685 (2016).</li><li>Kinoshita, E., Kinoshita-Kikuta, E., Takiyama, K., Koike, T. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Phosphate-binding+tag,+a+new+tool+to+visualize+phosphorylated+proteins.">Phosphate-binding tag, a new tool to visualize phosphorylated proteins.</a> Mol. Cell. Proteomics. 5 (4), 749-757 (2006).</li><li>Using a Hemacytometer to Count Cells. J. Vis. Exp Available from: <a target="_blank" href="https://www.jove.com/science-education/5048/using-a-hemacytometer-to-count-cells">https://www.jove.com/science-education/5048/using-a-hemacytometer-to-count-cells</a> (2017)</li><li>Ni, D., Xu, P., Gallagher, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Immunoblotting+and+Immunodetection.">Immunoblotting and Immunodetection.</a> Curr. Protoc. Mol. Biol. (114), 10.8.1-10.8.37 (2016).</li><li>Reith, A. D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=GSK2578215A;+a+potent+and+highly+selective+2-arylmethyloxy-5-substitutent-N-arylbenzamide+LRRK2+kinase+inhibitor.">GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.</a> Bioorg. Med. Chem. Lett. 22 (17), 5625-5629 (2012).</li><li>Fell, M. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=MLi-2,+a+potent,+selective+and+centrally+active+compound+for+exploring+the+therapeutic+potential+and+safety+of+LRRK2+kinase+inhibition.">MLi-2, a potent, selective and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition.</a> J. Pharmacol. Exp. Ther. 355, 397-409 (2015).</li><li>Dzamko, N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Inhibition+of+LRRK2+kinase+activity+leads+to+dephosphorylation+of+Ser(910)/Ser(935),+disruption+of+14-3-3+binding+and+altered+cytoplasmic+localization.">Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.</a> Biochem. J. 430 (3), 405-413 (2010).</li><li>Th&#233;venet, J., Pescini Gobert, R., Hooft van Huijsduijnen , R., Wiessner, C., Sagot, Y. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Regulation+of+LRRK2+expression+points+to+a+functional+role+in+human+monocyte+maturation.">Regulation of LRRK2 expression points to a functional role in human monocyte maturation.</a> PLoS One. 6 (6), e21519 (2011).</li></ol>

Here, we describe a facile and robust method of detecting Rab10 phosphorylation by LRRK2 at endogenous levels based on the P-tag methodology. Because the currently available antibody against phosphorylated Rab10 works only with overexpressed proteins15, the present method utilizing P-tag SDS-PAGE is the only way to assess endogenous levels of Rab10 phosphorylation. Moreover, the present method allows the estimation of the stoichiometry of Rab10 phosphorylation in cells. Because the P-tag methodolo...

PD is one of the most common neurodegenerative diseases, predominantly affecting dopaminergic neurons in the midbrain, resulting in dysfunction of the motor systems in elderly people1. While most patients develop PD in a sporadic manner, there are families inheriting the disease. Mutations in several genes have been found to be linked with FPD2. One of the causative genes for FPD is LRRK2, in which eight missense mutations (N1437H, R1441C/G/H/S, Y1699C, G2019S, and I2020T) linked to a dominantly inherited FPD called PARK8 have so far been reported3,4,5. Several genome-wide association studies (GWAS) of sporadic PD patients have also identified genomic variations at the LRRK2 locus as a risk factor for PD, suggesting that abnormality in the function of LRRK2 is a common cause of neurodegeneration in both sporadic and PARK8 FPD6,7,8.
LRRK2 is a large protein (2,527 amino acids) consisting of a leucine-rich repeat domain, a GTP-binding Ras of complex proteins (ROC) domain, a C-terminal of ROC (COR) domain, a serine/threonine protein kinase domain, and a WD40 repeat domain9. The eight FPD mutations locate in these functional domains; N1437H and R1441C/G/H/S in the ROC domain, Y1699C in the COR domain, G2019S and I2020T in the kinase domain. Since G2019S mutation, which is the most frequently found mutation in PD patients10,11,12, increases the kinase activity of LRRK2 by 2 - 3 fold in vitro13, it is hypothesized that the abnormal increase in phosphorylation of LRRK2 substrate(s) is toxic to neurons. However, it has been impossible to study whether the phosphorylation of physiologically relevant LRRK2 substrates is altered in familial/sporadic PD patients due to the lack of methods evaluating it in patient derived samples.
Protein phosphorylation is generally detected by immunoblotting or enzyme-linked immunosorbent assay (ELISA) using antibodies specifically recognizing the phosphorylated state of proteins or by mass spectrometric analysis. However, the former strategy sometimes cannot be applied because of the difficulties in creating phosphorylation-specific antibodies. Metabolic labeling of cells with radioactive phosphate is another option to examine physiological levels of phosphorylation when phosphorylation-specific antibodies are not readily available. However, it requires a large amount of radioactive materials and therefore involves some specialized equipment for radioprotection14. Mass spectrometric analysis is more sensitive compared to these immunochemical methods and became popular in analyzing protein phosphorylation. However, the sample preparation is time-consuming, and expensive instruments are required for the analysis.
A subset of the Rab GTPase family including Rab10 and Rab8 was recently reported as direct physiological substrates for LRRK2 based on the result of a large-scale phosphoproteomic analysis15. We then demonstrated that Rab10 phosphorylation was increased by FPD mutations in mouse embryonic fibroblasts and in the lungs of knockin mice16. In this report, we chose to employ a sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)-based method in which a P-tag molecule is co-polymerized into SDS-PAGE gels (P-tag SDS-PAGE) for detecting the endogenous levels of Rab10 phosphorylation, because a highly sensitive antibody specific for phosphorylated Rab10 was still lacking. We have failed to detect the phosphorylation of endogenous Rab8 due to the poor selectivity of currently available antibodies for total Rab8. Therefore, we decided to focus on the Rab10 phosphorylation. LRRK2 phosphorylates Rab10 at Thr73 locating at the middle of the highly conserved &#34;switch II&#34; region. High conservation of the phosphorylation sites among Rab proteins might be one of the reasons why phosphospecific antibodies recognizing distinct Rab proteins are difficult to make.
The phosphorylation of Rab8A by LRRK2 inhibits the binding of Rabin8, a guanine nucleotide exchange factor (GEF) which activates Rab8A by exchanging the bound GDP with GTP15. Phosphorylation of Rab10 and Rab8A by LRRK2 also inhibits the binding of GDP-dissociation inhibitors (GDIs), which are essential to the activation of Rab proteins by extracting GDP-bound Rab proteins from membranes15. Collectively, it is hypothesized that the phosphorylation of Rab proteins by LRRK2 prevents them from activation although the precise molecular mechanism and physiological consequences of the phosphorylation remain unclear.
P-tag SDS-PAGE was invented by Kinoshita et al. in 2006: In this method, acrylamide was covalently coupled with P-tag, a molecule capturing phosphates with high affinity, which copolymerized into SDS-PAGE gels17. Because the P-tag molecules in a SDS-PAGE gel selectively retard electrophoretic mobility of phosphorylated proteins, P-tag SDS-PAGE can separate phosphorylated proteins from non-phosphorylated ones (Figure 1). If the protein-of-interest is phosphorylated on multiple residues, a ladder of bands corresponding to differentially phosphorylated forms will be observed. In the case of Rab10, we observe only one shifted band, indicating that Rab10 is phosphorylated only at Thr73. The major advantage of P-tag SDS-PAGE over immunoblotting with phosphorylation-specific antibodies is that phosphorylated Rab10 can be detected by immunoblotting with non-phosphorylation-specific antibodies (i.e., recognizing total Rab10) after being transferred on membranes, which is generally more specific, sensitive, and available from commercial/academic sources. Another advantage of using P-tag SDS-PAGE is that one can obtain approximate estimation of the stoichiometry of phosphorylation, which is impossible by immunoblotting with phosphorylation-specific antibodies or by metabolic labeling of cells with radioactive phosphates.
Apart from the use of inexpensive P-tag acrylamide and some minor modifications related to it, the present method for detection of Rab10 phosphorylation by LRRK2 follows a general protocol of immunoblotting. Therefore, it should be straightforward and easily executable in any laboratories where immunoblotting is a usual practice, with any types of samples including purified proteins, cell lysates, and tissue homogenates.

<table>
	<tbody>
		<tr>
			<td>Reagents</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Dulbecco&#39;s phosphate-buffered saline (DPBS)</td>
			<td>homemade</td>
			<td></td>
			<td>150 mM NaCl, 8 mM Na2HPO4-12H2O, 2.7 mM KCl, 1.5 mM KH2PO4 in MilliQ water and sterilized by autoclaving</td>
		</tr>
		<tr>
			<td>Sodium chloride</td>
			<td>Nacalai Tesque</td>
			<td>31320-34</td>
			<td></td>
		</tr>
		<tr>
			<td>Sodium Disodium Hydrogenphosphate 12-Water</td>
			<td>Wako</td>
			<td>196-02835</td>
			<td></td>
		</tr>
		<tr>
			<td>Potassium chloride</td>
			<td>Wako</td>
			<td>163-03545</td>
			<td></td>
		</tr>
		<tr>
			<td>Potassium Dihydrogen Phosphate</td>
			<td>Wako</td>
			<td>169-04245</td>
			<td></td>
		</tr>
		<tr>
			<td>2.5% Trypsin (10X)</td>
			<td>Sigma-Aldrich</td>
			<td>T4549</td>
			<td>Dilute 10-fold with sterile DPBS for preparing working solution</td>
		</tr>
		<tr>
			<td>Dulbecco&#39;s modified Eagle medium 
			(DMEM)</td>
			<td>Wako</td>
			<td>044-29765</td>
			<td></td>
		</tr>
		<tr>
			<td>Fetal bovine serum</td>
			<td>BioWest</td>
			<td>S1560</td>
			<td>Heat-inactivated at 56 &#176;C for 30 min</td>
		</tr>
		<tr>
			<td>Penicillin-Streptomycin (100X)</td>
			<td>Wako</td>
			<td>168-23191</td>
			<td></td>
		</tr>
		<tr>
			<td>HEPES</td>
			<td>Wako</td>
			<td>342-01375</td>
			<td></td>
		</tr>
		<tr>
			<td>Sodium hydroxide</td>
			<td>Wako</td>
			<td>198-13765</td>
			<td></td>
		</tr>
		<tr>
			<td>Polyethylenimine HCl MAX, Linear, Mw 40,000 (PEI MAX 40000)</td>
			<td>PolySciences, Inc.</td>
			<td>24765-1</td>
			<td>Stock solution was prepared in 20 mM HEPES-NaOH pH 7.0 at 1 mg/mL and the pH was then adjusted to 7.0 with NaOH</td>
		</tr>
		<tr>
			<td>Dimethyl sulfoxide</td>
			<td>Wako</td>
			<td>045-28335</td>
			<td></td>
		</tr>
		<tr>
			<td>Tris</td>
			<td>STAR</td>
			<td>RSP-THA500G</td>
			<td></td>
		</tr>
		<tr>
			<td>Hydrochloric acid</td>
			<td>Wako</td>
			<td>080-01066</td>
			<td></td>
		</tr>
		<tr>
			<td>Polyoxyethylene(10) Octylphenyl Ether</td>
			<td>Wako</td>
			<td>160-24751</td>
			<td>Equivalent to Triton X-100</td>
		</tr>
		<tr>
			<td>Ethylene glycol-bis(2-aminoethylether)-N,N,N&#8217;,N&#8217;-tetraacetic acid (EGTA)</td>
			<td>Wako</td>
			<td>346-01312</td>
			<td></td>
		</tr>
		<tr>
			<td>Sodium orthovanadate(V)</td>
			<td>Wako</td>
			<td>198-09752</td>
			<td></td>
		</tr>
		<tr>
			<td>Sodium fluoride</td>
			<td>Kanto Chemical</td>
			<td>37174-20</td>
			<td></td>
		</tr>
		<tr>
			<td>&#946;-Glycerophosphoric Acid Disodium Salt Pentahydrate</td>
			<td>Nacalai Tesque</td>
			<td>17103-82</td>
			<td></td>
		</tr>
		<tr>
			<td>Sodium pyrophosphate decahydrate</td>
			<td>Kokusan Chemical</td>
			<td>2113899</td>
			<td></td>
		</tr>
		<tr>
			<td>Microcystin-LR</td>
			<td>Wako</td>
			<td>136-12241</td>
			<td></td>
		</tr>
		<tr>
			<td>Sucrose</td>
			<td>Wako</td>
			<td>196-00015</td>
			<td></td>
		</tr>
		<tr>
			<td>Complete EDTA-free protease inhibitor cocktail</td>
			<td>Roche</td>
			<td>11873580001</td>
			<td>Dissolve one tablet in 1 mL water, which can be stored at -20 &#176;C for a month. Use it at 1:50 dilution for cell lysis</td>
		</tr>
		<tr>
			<td>Pierce Coomassie (Bradford) Protein Assay Kit</td>
			<td>Thermo Fisher Scientific</td>
			<td>23200</td>
			<td></td>
		</tr>
		<tr>
			<td>Sodium dodecyl sulfate</td>
			<td>Nacalai Tesque</td>
			<td>31607-65</td>
			<td></td>
		</tr>
		<tr>
			<td>Glycerol</td>
			<td>Wako</td>
			<td>075-00616</td>
			<td></td>
		</tr>
		<tr>
			<td>Bromophenol blue</td>
			<td>Wako</td>
			<td>021-02911</td>
			<td></td>
		</tr>
		<tr>
			<td>&#946;-mercaptoethanol</td>
			<td>Kanto Chemical</td>
			<td>25099-00</td>
			<td></td>
		</tr>
		<tr>
			<td>Ethanol</td>
			<td>Wako</td>
			<td>056-06967</td>
			<td></td>
		</tr>
		<tr>
			<td>Methanol</td>
			<td>Wako</td>
			<td>136-01837</td>
			<td></td>
		</tr>
		<tr>
			<td>Phosphate-binding tag acrylamide</td>
			<td>Wako</td>
			<td>AAL-107</td>
			<td>P-tag acrylamide</td>
		</tr>
		<tr>
			<td>40% (w/v) acrylamide solution</td>
			<td>Nacalai Tesque</td>
			<td>06119-45</td>
			<td>Acrylamide:Bis = 29:1</td>
		</tr>
		<tr>
			<td>Tetramethylethylenediamine (TEMED)</td>
			<td>Nacalai Tesque</td>
			<td>33401-72</td>
			<td></td>
		</tr>
		<tr>
			<td>Ammonium persulfate (APS)</td>
			<td>Wako</td>
			<td>016-08021</td>
			<td>10% (w/v) solution was prepared by dissolving the powder of ammonium persulfate in MilliQ water</td>
		</tr>
		<tr>
			<td>2-propanol</td>
			<td>Wako</td>
			<td>166-04831</td>
			<td></td>
		</tr>
		<tr>
			<td>Manganese chloride tetrahydrate</td>
			<td>Sigma-Aldrich</td>
			<td>M3634</td>
			<td></td>
		</tr>
		<tr>
			<td>Precision Plus Protein Prestained Standard</td>
			<td>Bio-Rad</td>
			<td>1610374, 1610373, 1610377</td>
			<td>Molecular weight marker used in the protocol</td>
		</tr>
		<tr>
			<td>WIDE-VIEW Prestained Protein Size Marker III</td>
			<td>Wako</td>
			<td>230-02461</td>
			<td></td>
		</tr>
		<tr>
			<td>Glycine</td>
			<td>Nacalai Tesque</td>
			<td>17109-64</td>
			<td></td>
		</tr>
		<tr>
			<td>Amersham Protran NC 0.45</td>
			<td>GE Healthcare</td>
			<td>10600007</td>
			<td>Nitrocellulose membrane</td>
		</tr>
		<tr>
			<td>Durapore Membrane Filter</td>
			<td>EMD Millipore</td>
			<td>GVHP00010</td>
			<td>PVDF membrane</td>
		</tr>
		<tr>
			<td>Filter Papers No.1</td>
			<td>Advantec</td>
			<td>00013600</td>
			<td></td>
		</tr>
		<tr>
			<td>Ponceau S</td>
			<td>Nacalai Tesque</td>
			<td>28322-72</td>
			<td></td>
		</tr>
		<tr>
			<td>Acetic acid</td>
			<td>Wako</td>
			<td>017-00251</td>
			<td></td>
		</tr>
		<tr>
			<td>Tween-20</td>
			<td>Sigma-Aldrich</td>
			<td>P1379</td>
			<td>polyoxyethylenesorbitan monolaurate</td>
		</tr>
		<tr>
			<td>Ethylenediaminetetraacetic acid (EDTA)</td>
			<td>Wako</td>
			<td>345-01865</td>
			<td></td>
		</tr>
		<tr>
			<td>Skim milk powder</td>
			<td>Difco Laboratories</td>
			<td>232100</td>
			<td></td>
		</tr>
		<tr>
			<td>Immunostar</td>
			<td>Wako</td>
			<td>291-55203</td>
			<td>ECL solution (Normal sensitivity)</td>
		</tr>
		<tr>
			<td>Immunostar LD</td>
			<td>Wako</td>
			<td>290-69904</td>
			<td>ECL solution (High sensitivity)</td>
		</tr>
		<tr>
			<td>CBB staining solution</td>
			<td>homemade</td>
			<td></td>
			<td>1 g CBB R-250, 50% (v/v) methanol, 10% (v/v) acetic acid in 1 L of MilliQ water</td>
		</tr>
		<tr>
			<td>CBB R-250</td>
			<td>Wako</td>
			<td>031-17922</td>
			<td></td>
		</tr>
		<tr>
			<td>CBB destaining solution</td>
			<td>homemade</td>
			<td></td>
			<td>12% (v/v) methanol, 7% (v/v) acetic acid in 1 L MilliQ water</td>
		</tr>
		<tr>
			<td>Name</td>
			<td>Company</td>
			<td>Catalog Number</td>
			<td>Comments</td>
		</tr>
		<tr>
			<td>Antibodies</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>anti-HA antibody</td>
			<td>Sigma-Aldrich</td>
			<td>11583816001</td>
			<td>Used at 0.2 &#956;g/mL for immunoblotting.</td>
		</tr>
		<tr>
			<td>anti-Rab10 antibody</td>
			<td>Cell Signaling Technology</td>
			<td>#8127</td>
			<td>Used at 1:1000 for immunoblotting. 
			Specificity was confirmed by CRISPR KO in Ito et al., Biochem J, 2016.</td>
		</tr>
		<tr>
			<td>anti-pSer935 antibody</td>
			<td>Abcam</td>
			<td>ab133450</td>
			<td>Used at 1 &#956;g/mL for immunoblotting.</td>
		</tr>
		<tr>
			<td>anti-LRRK2 antibody</td>
			<td>Abcam</td>
			<td>ab133518</td>
			<td>Used at 1 &#956;g/mL for immunoblotting.</td>
		</tr>
		<tr>
			<td>anti-&#945;-tubulin antibody</td>
			<td>Sigma-Aldrich</td>
			<td>T9026</td>
			<td>Used at 1 &#956;g/mL for immunoblotting.</td>
		</tr>
		<tr>
			<td>anti-GAPDH antibody</td>
			<td>Santa-Cruz</td>
			<td>sc-32233</td>
			<td>Used at 0.02 &#956;g/mL for immunoblotting.</td>
		</tr>
		<tr>
			<td>Peroxidase AffiniPure Sheep Anti-Mouse IgG (H+L)</td>
			<td>Jackson ImmunoResearch</td>
			<td>515-035-003</td>
			<td>Used at 0.16 &#956;g/mL for immunoblotting.</td>
		</tr>
		<tr>
			<td>Peroxidase AffiniPure Goat Anti-Rabbit IgG (H+L)</td>
			<td>Jackson ImmunoResearch</td>
			<td>111-035-003</td>
			<td>Used at 0.16 &#956;g/mL for immunoblotting.</td>
		</tr>
		<tr>
			<td>Name</td>
			<td>Company</td>
			<td>Catalog Number</td>
			<td>Comments</td>
		</tr>
		<tr>
			<td>Inhibitors</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>GSK2578215A</td>
			<td>MedChem Express</td>
			<td>HY-13237</td>
			<td>Stock solution was prepared in DMSO at 10 mM and stored at -80 &#176;C</td>
		</tr>
		<tr>
			<td>MLi-2</td>
			<td>Provided by Dr Dario Alessi (University of Dundee)</td>
			<td></td>
			<td>Stock solution was prepared in DMSO at 10 mM and stored at -80 &#176;C</td>
		</tr>
		<tr>
			<td>Name</td>
			<td>Company</td>
			<td>Catalog Number</td>
			<td>Comments</td>
		</tr>
		<tr>
			<td>Plasmids</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Rab10/pcDNA5 FRT TO HA</td>
			<td>Provided by Dr Dario Alessi 
			(University of Dundee)</td>
			<td></td>
			<td>This plasmid expresses amino-terminally HA-tagged human Rab10.</td>
		</tr>
		<tr>
			<td>LRRK2 WT/p3xFLAG-CMV-10</td>
			<td>Provided by Dr Takeshi Iwatsubo (University of Tokyo)</td>
			<td></td>
			<td>Ito et al., Biochemistry, 46: 1380&#8211;1388 (2007). This plasmid expresses amino-terminally 3xFLAG-tagged wild-type human LRRK2.</td>
		</tr>
		<tr>
			<td>LRRK2 K1906M/p3xFLAG-CMV-10</td>
			<td>Provided by Dr Takeshi Iwatsubo (University of Tokyo)</td>
			<td></td>
			<td>Ito et al., Biochemistry, 46: 1380&#8211;1388 (2007). This plasmid expresses amino-terminally 3xFLAG-tagged K1906M kinase-inactive mutant of human LRRK2.</td>
		</tr>
		<tr>
			<td>LRRK2 N1437H/p3xFLAG-CMV-10</td>
			<td></td>
			<td></td>
			<td>This paper. This plasmid expresses amino-terminally 3xFLAG-tagged N1437H FPD mutant of human LRRK2.</td>
		</tr>
		<tr>
			<td>LRRK2 R1441C/p3xFLAG-CMV-10</td>
			<td>Provided by Dr Takeshi Iwatsubo (University of Tokyo)</td>
			<td></td>
			<td>Kamikawaji et al., Biochemistry, 48: 10963&#8211;10975 (2013). This plasmid expresses amino-terminally 3xFLAG-tagged R1441C FPD mutant of human LRRK2.</td>
		</tr>
		<tr>
			<td>LRRK2 R1441G/p3xFLAG-CMV-10</td>
			<td>Provided by Dr Takeshi Iwatsubo (University of Tokyo)</td>
			<td></td>
			<td>Kamikawaji et al., Biochemistry, 48: 10963&#8211;10975 (2013). This plasmid expresses amino-terminally 3xFLAG-tagged R1441G FPD mutant of human LRRK2.</td>
		</tr>
		<tr>
			<td>LRRK2 R1441H/p3xFLAG-CMV-10</td>
			<td>Provided by Dr Takeshi Iwatsubo (University of Tokyo)</td>
			<td></td>
			<td>Kamikawaji et al., Biochemistry, 48: 10963&#8211;10975 (2013). This plasmid expresses amino-terminally 3xFLAG-tagged R1441H FPD mutant of human LRRK2.</td>
		</tr>
		<tr>
			<td>LRRK2 R1441S/p3xFLAG-CMV-10</td>
			<td></td>
			<td></td>
			<td>This paper. This plasmid expresses amino-terminally 3xFLAG-tagged R1441S FPD mutant of human LRRK2.</td>
		</tr>
		<tr>
			<td>LRRK2 Y1699C/p3xFLAG-CMV-10</td>
			<td>Provided by Dr Takeshi Iwatsubo (University of Tokyo)</td>
			<td></td>
			<td>Kamikawaji et al., Biochemistry, 48: 10963&#8211;10975 (2013). This plasmid expresses amino-terminally 3xFLAG-tagged Y1699C FPD mutant of human LRRK2.</td>
		</tr>
		<tr>
			<td>LRRK2 G2019S/p3xFLAG-CMV-10</td>
			<td>Provided by Dr Takeshi Iwatsubo (University of Tokyo)</td>
			<td></td>
			<td>Kamikawaji et al., Biochemistry, 48: 10963&#8211;10975 (2013). This plasmid expresses amino-terminally 3xFLAG-tagged G2019S FPD mutant of human LRRK2.</td>
		</tr>
		<tr>
			<td>LRRK2 I2020T/p3xFLAG-CMV-10</td>
			<td>Provided by Dr Takeshi Iwatsubo (University of Tokyo)</td>
			<td></td>
			<td>Kamikawaji et al., Biochemistry, 48: 10963&#8211;10975 (2013). This plasmid expresses amino-terminally 3xFLAG-tagged I2020T FPD mutant of human LRRK2.</td>
		</tr>
		<tr>
			<td>Name</td>
			<td>Company</td>
			<td>Catalog Number</td>
			<td>Comments</td>
		</tr>
		<tr>
			<td>Equipments</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>CO2 incubator</td>
			<td>Thermo Fisher Scientific</td>
			<td>Forma Series II 3110 Water-Jacketed</td>
			<td></td>
		</tr>
		<tr>
			<td>Auto Pipette</td>
			<td>Drummond</td>
			<td>Pipet-Aid PA-400</td>
			<td></td>
		</tr>
		<tr>
			<td>Micropipette P10</td>
			<td>Nichiryo</td>
			<td>00-NPX2-10</td>
			<td>0.5&#8211;10 &#956;L</td>
		</tr>
		<tr>
			<td>Micropipette P200</td>
			<td>Nichiryo</td>
			<td>00-NPX2-200</td>
			<td>20&#8211;200 &#956;L</td>
		</tr>
		<tr>
			<td>Micropipette P1000</td>
			<td>Nichiryo</td>
			<td>00-NPX2-1000</td>
			<td>100&#8211;1000 &#956;L</td>
		</tr>
		<tr>
			<td>Tips for micropipette P10</td>
			<td>STAR</td>
			<td>RST-481LCRST</td>
			<td>Sterile</td>
		</tr>
		<tr>
			<td>Tips for micropipette P200</td>
			<td>FUKAEKASEI</td>
			<td>1201-705YS</td>
			<td>Sterile</td>
		</tr>
		<tr>
			<td>Tips for micropipette P1000</td>
			<td>STAR</td>
			<td>RST-4810BRST</td>
			<td>Sterile</td>
		</tr>
		<tr>
			<td>5 mL disporsable pipette</td>
			<td>Greiner</td>
			<td>606180</td>
			<td>Sterile</td>
		</tr>
		<tr>
			<td>10 mL disporsable pipette</td>
			<td>Greiner</td>
			<td>607180</td>
			<td>Sterile</td>
		</tr>
		<tr>
			<td>25 mL disporsable pipette</td>
			<td>Falcon</td>
			<td>357535</td>
			<td>Sterile</td>
		</tr>
		<tr>
			<td>Hematocytometer</td>
			<td>Sunlead Glass</td>
			<td>A126</td>
			<td>Improved Neubeuer</td>
		</tr>
		<tr>
			<td>Microscope</td>
			<td>Olympus</td>
			<td>CKX53</td>
			<td></td>
		</tr>
		<tr>
			<td>10 cm dishes</td>
			<td>Falcon</td>
			<td>353003</td>
			<td>For tissue culture</td>
		</tr>
		<tr>
			<td>6-well plates</td>
			<td>AGC Techno Glass</td>
			<td>3810-006</td>
			<td>For tissue culture</td>
		</tr>
		<tr>
			<td>Vortex mixer</td>
			<td>Scientific Industries</td>
			<td>Vortex-Genie 2</td>
			<td></td>
		</tr>
		<tr>
			<td>Cell scrapers</td>
			<td>Sumitomo Bakelite</td>
			<td>MS-93100</td>
			<td></td>
		</tr>
		<tr>
			<td>1.5 mL tubes</td>
			<td>STAR</td>
			<td>RSV-MTT1.5</td>
			<td></td>
		</tr>
		<tr>
			<td>15 mL tubes</td>
			<td>AGC Techno Glass</td>
			<td>2323-015</td>
			<td></td>
		</tr>
		<tr>
			<td>50 mL tubes</td>
			<td>AGC Techno Glass</td>
			<td>2343-050</td>
			<td></td>
		</tr>
		<tr>
			<td>Centrifuges</td>
			<td>TOMY</td>
			<td>MX-307</td>
			<td></td>
		</tr>
		<tr>
			<td>96-well plates</td>
			<td>Greiner</td>
			<td>655061</td>
			<td>Not for tissue culture</td>
		</tr>
		<tr>
			<td>Plate reader</td>
			<td>Molecular Devices</td>
			<td>SpectraMax M2e</td>
			<td></td>
		</tr>
		<tr>
			<td>SDS&#8211;PAGE tanks</td>
			<td>Nihon Eido</td>
			<td>NA-1010</td>
			<td></td>
		</tr>
		<tr>
			<td>Transfer tanks</td>
			<td>Nihon Eido</td>
			<td>NA-1510B</td>
			<td></td>
		</tr>
		<tr>
			<td>Gel plates (notched)</td>
			<td>Nihon Eido</td>
			<td>NA-1000-1</td>
			<td></td>
		</tr>
		<tr>
			<td>Gel plates (plain)</td>
			<td>Nihon Eido</td>
			<td>NA-1000-2</td>
			<td></td>
		</tr>
		<tr>
			<td>Silicon spacers</td>
			<td>Nihon Eido</td>
			<td>NA-1000-16</td>
			<td></td>
		</tr>
		<tr>
			<td>17-well combs</td>
			<td>Nihon Eido</td>
			<td>Custom made</td>
			<td></td>
		</tr>
		<tr>
			<td>Binder clips</td>
			<td>Nihon Eido</td>
			<td>NA-1000-15</td>
			<td></td>
		</tr>
		<tr>
			<td>5 mL syringe</td>
			<td>Terumo</td>
			<td>SS-05SZ</td>
			<td></td>
		</tr>
		<tr>
			<td>21G</td>
			<td>Terumo</td>
			<td>NN-2138R</td>
			<td></td>
		</tr>
		<tr>
			<td>Power Station 1000 VC</td>
			<td>ATTO</td>
			<td>AE-8450</td>
			<td>Power supply for SDS&#8211;PAGE and transfer</td>
		</tr>
		<tr>
			<td>Large weighing boats</td>
			<td>Ina Optika</td>
			<td>AS-DL</td>
			<td></td>
		</tr>
		<tr>
			<td>Plastic containers</td>
			<td>AS ONE</td>
			<td>PS CASE No.4</td>
			<td>10 x 80 x 50 mm</td>
		</tr>
		<tr>
			<td>Rocking shaker</td>
			<td>Titech</td>
			<td>NR-10</td>
			<td></td>
		</tr>
		<tr>
			<td>Styrene foam box</td>
			<td>generic</td>
			<td></td>
			<td>The internal dimensions should fit one transfer tank (200 x 250 x 250 mm).</td>
		</tr>
		<tr>
			<td>ImageQuant LAS-4000</td>
			<td>GE Healthcare</td>
			<td></td>
			<td>An imager equipped with a cooled CCD camera for detection of ECL</td>
		</tr>
	</tbody>
</table>

rab10 phosphorylation detection by lrrk2 activity using sds-page with a phosphate-binding tag

Mutations in leucine-rich repeat kinase 2 (LRRK2) have been shown to be linked with familial Parkinson&#39;s disease (FPD). Since abnormal activation of the kinase activity of LRRK2 has been implicated in the pathogenesis of PD, it is essential to establish a method to evaluate the physiological levels of the kinase activity of LRRK2. Recent studies revealed that LRRK2 phosphorylates members of the Rab GTPase family, including Rab10, under physiological conditions. Although the phosphorylation of endogenous Rab10 by LRRK2 in cultured cells could be detected by mass spectrometry, it has been difficult to detect it by immunoblotting due to the poor sensitivity of currently available phosphorylation-specific antibodies for Rab10. Here, we describe a simple method of detecting the endogenous levels of Rab10 phosphorylation by LRRK2 based on immunoblotting utilizing sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) combined with a phosphate-binding tag (P-tag), which is N-(5-(2-aminoethylcarbamoyl)pyridin-2-ylmetyl)-N,N&#39;,N&#39;-tris(pyridin-2-yl-methyl)-1,3-diaminopropan-2-ol. The present protocol not only provides an example of the methodology utilizing the P-tag but also enables the assessment of how mutations as well as inhibitor treatment/administration or any other factors alter the downstream signaling of LRRK2 in cells and tissues.

Overexpression System: Phosphorylation of HA-Rab10 by 3&#215;FLAG-LRRK2 in HEK293 Cells:
HEK293 cells were transfected with 0.266 &#181;g of HA-Rab10 wild-type and 1.066 &#181;g of 3&#215;FLAG-LRRK2 (wild-type, kinase-inactive mutant (K1906M), or FPD mutants). Rab10 phosphorylation was examined by P-tag SDS-PAGE followed by immunoblotting using an anti-HA antibody (Figure 2). 10 &#181;g of proteins wer...

The present study describes a simple method of detecting endogenous levels of Rab10 phosphorylation by leucine-rich repeat kinase 2.

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag

Mutations in leucine-rich repeat kinase 2 (LRRK2) have been shown to be linked with familial Parkinson&#39;s disease (FPD). Since abnormal activation of ...

The overall goal of this experiment is to detect the Rab10 phosphorylation by LRRK2 using SDS-PAGE with a phosphate-binding tag. This method can help answer key questions in the Parkinson research field such as how disease mutations in LRRK2 affect Rab10 phosphorylation. The main advantage of this technique is that one can have a rough estimation of the stoichiometry of Rab10 phosphorylation using a simple western blot.Many of the steps of this protocol are fairly standard and are described in sufficient detail by the text protocol accompanying this video. Here, we want to show you the steps that benefit most from visual instruction. Prepare plates of transfected HEK293 cells as described in the text protocol.With the plates on ice, aspirate and discard the media. Next, carefully add two milliliters of DPBS to the corner of each plate and rock the plates to spread the solution. Then remove and discard the DPBS.Next, to each plate add 100 microliters of lysis buffer. Tilt the plate and use a scraper to spread the buffer and release the cell lysate. Then aspirate the lysates and transfer them to microfuge tubes prechilled on ice and wait 10 minutes.Next, collect debris-free cell lysates by centrifuging the tubes and transferring the supernatants to new tubes on ice. Then measure the protein concentrations of the cleared lysates using the Bradford assay. For the concentration data, prepare 100 microliter samples of the lysates for the gel analysis.Prepare denser lysates to measure endogenous Rab10 compared to overexpressed hemagglutinin Rab10. Finish the preparation of the samples by incubating them at 100 degrees Celsius for five minutes. Then store the samples below minus 20 degrees Celsius until needed for up to six months or longer.To begin, prepare the SDS-PAGE cells according to the text protocol. Then load the gel into the tank and secure it with binder clips. Next, fill the tank with running buffer and remove the air bubbles in the wells and under the gel using a needle attached to a syringe.Now add manganese chloride to the samples and spin them down to remove the precipitates. Then load the gel with equal volumes of sample, 10 micrograms of protein to analyze overexpressed hemagglutinin Rab10 or 30 micrograms of protein to analyze endogenous Rab10. Load the empty lanes with sample buffer containing manganese chloride.Also supplement the molecular weight marker with buffer and manganese chloride to make it the same volume as the samples. Now start running the gel at 50 volts. After the sample stack, increase the voltage to 120 to get separation.When the dye front reaches the bottom of the gels, kill the voltage. Next, wash the gel three times as follows. Load the separation gel into a bath of clean transfer buffer with added EDTA and SDS.Then let it rock on a shaker for 10 minutes at room temperature. After three washes, perform one more wash using transfer buffer with added SDS but without EDTA. Then transfer the gel using a wet tank.Load the tank into a foam box filled with ice cold water, connect the tank to a power supply and start the transfer. A long transfer with efficient cooling is essential to the procedure. After the transfer, check the transfer by staining the membrane with Ponceau S, followed by a wash in TBST according to the text protocol.Next, apply a block. Immerse the blot in milky TBST and rock the blot on a shaker for an hour at room temperature. Then remove and discard the blocking solution and apply the primary antibody solution.Now rock the membrane overnight at four degrees Celsius. The next day, remove the primary antibody solution. Then wash the membrane with fresh TBST three times as before.After the washes, immerse the blot in secondary antibody solution and incubate the membrane on a rocker for about an hour at room temperature. After the incubation, wash the membrane with TBST three times once again. Now develop the membrane.Add one milliliter of ECL solution to a large sheet of plastic wrap. Then lay the membrane into the ECL and quickly flip it over to wet both sides. Next, lift the membrane and let it drain.After draining, let one edge touch a paper towel for about five seconds to help wick off excess solution. Then wrap the membrane in stiff clear film without wrinkles and transfer it to a black tray for imaging. HEK293 cells were transfected with hemagglutinin Rab10 wild-type and 3xFLAG-LRRK2.Wild-type kinase inactive in familial Parkinson disease mutations of LRRK2 were tested. Co-overexpression of LRRK2 and Rab10 resulted in a major band shift in the P-tag gel. In contrast, co-expression with a kinase inactive mutant resulted in no change in Rab10 mobility, implicating the kinase as the cause of the band shift.Also as expected, the familial PD mutations all increased the band shift. The P-tag gel system was also used to analyze mouse 3T3-Swiss albino embryonic fibroblast cells treated with a LRRK2 inhibitor. The band shift corresponding to phosphorylated endogenous Rab10 disappeared when the cells were treated with GSK2578215A.The same test was also performed using human A549 cells. In these experiments, the efficacy of the LRRK2 inhibitor was validated using the anti-p serine 935 LRRK2 antibody which is a well-established marker of LRRK2 inhibition. Once mastered, this technique only needs additional 14 minutes compared to a regular western blotting procedure which is for washing gels before transfer.Following this procedure, other methods like mass spectrometry can be performed in order to answer additional questions like whether FPD mutants phosphorylate the same residue of Rab10. After its development, this technique paved the way for researchers in the field of Parkinson research to explore the endogenous levels of Rab10 phosphorylation in cultured cells as well as in tissues. Don't forget that working with microcystin added to the lysis buffer can be extremely hazardous and precautions such as wearing appropriate personal protective equipment should always be taken while preparing cell lysates.

Research

JoVE Journal

Biochemistry

Highly Sensitive and Rapid Fluorescence Detection with a Portable FRET Analyzer

Recent improvements in F&#246;rster resonance energy transfer (FRET) sensors have enabled their use to detect various small molecules including ions and ...

Detection of the pH-dependent Activity of Escherichia coli Chaperone HdeB In Vitro and In Vivo

Bacteria are frequently exposed to environmental changes, such as alterations in pH, temperature, redox status, light exposure or mechanical force. Many ...

Oligopeptide Competition Assay for Phosphorylation Site Determination

Protein phosphorylation at specific sites determines its conformation and interaction with other molecules. Thus, protein phosphorylation affects ...

DNA Polymerase Activity Assay Using Near-infrared Fluorescent Labeled DNA Visualized by Acrylamide Gel Electrophoresis

For any enzyme, robust, quantitative methods are required for characterization of both native and engineered enzymes. For DNA polymerases, DNA synthesis ...

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and  GTPase-linked Immunosorbent Assay

The Rho GTPase family belongs to the Ras superfamily and includes approximately 20 members in humans. Rho GTPases are important in the regulation of ...

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Cyclin-dependent kinase 1 (Cdk1) is a master controller for the cell cycle in all eukaryotes and phosphorylates an estimated 8 - 13% of the proteome; ...

Affinity Purification of Chloroplast Translocon Protein Complexes Using the TAP Tag

Chloroplast biogenesis requires the import of thousands of nucleus-encoded proteins into the plastid. The import of these proteins depends on the ...

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

The leucine rich repeat kinase 2 (LRRK2) is the most frequently mutated gene in hereditary Parkinson&#8217; disease (PD) and all pathogenic LRRK2 ...

Detection of Protein Ubiquitination Sites by Peptide Enrichment and Mass Spectrometry

The posttranslational modification of proteins by the small protein ubiquitin is involved in many cellular events. After tryptic digestion of ...

Kinetic Screening of Nuclease Activity using Nucleic Acid Probes

Nucleases are a class of enzymes that break down nucleic acids by catalyzing the hydrolysis of the phosphodiester bonds that link the ribose sugars. ...